As always, FFF goes Beyond Distribution in its commitment to lead with integrity and a patient-centered focus. We are constantly seeking innovative solutions to reinforce the safety of the supply chain and add extra value to patient care to benefit our manufacturer partners and customers.

Everything we do affirms our dedication to forge a reliable, secure pharmaceutical supply chain in the pursuit of our mission of Helping Healthcare Care®.
# Pediatric Vaccine Products

<table>
<thead>
<tr>
<th>Product</th>
<th>Manufacturer</th>
<th>Size</th>
<th>NDC ‡</th>
<th>Code*</th>
<th>VIPc</th>
<th>340B</th>
</tr>
</thead>
<tbody>
<tr>
<td>DTaP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DAPTACEL®</td>
<td>Sanofi Pasteur</td>
<td>10 SDV/bx</td>
<td>49281-0286-10</td>
<td>90700</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>INFANRIX®</td>
<td>GSK</td>
<td>0.5 mL SDV 10-pk</td>
<td>58160-0810-11</td>
<td>90700</td>
<td>TBD</td>
<td>Yes</td>
</tr>
<tr>
<td>INFANRIX®</td>
<td>GSK</td>
<td>0.5 mL PFS 10-pk</td>
<td>58160-0810-52</td>
<td>90700</td>
<td>TBD</td>
<td>Yes</td>
</tr>
<tr>
<td>DTaP, Polio</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KINRIX®</td>
<td>GSK</td>
<td>0.5 mL SDV 10-pk</td>
<td>58160-0812-11</td>
<td>90696</td>
<td>TBD</td>
<td>Yes</td>
</tr>
<tr>
<td>KINRIX®</td>
<td>GSK</td>
<td>0.5 mL PFS 10-pk</td>
<td>58160-0812-52</td>
<td>90696</td>
<td>TBD</td>
<td>Yes</td>
</tr>
<tr>
<td>DTaP, Hepatitis B, Polio</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PEDIARIX®</td>
<td>GSK</td>
<td>0.5 mL PFS 10-pk</td>
<td>58160-0811-52</td>
<td>90723</td>
<td>TBD</td>
<td>Yes</td>
</tr>
<tr>
<td>DTaP, Polio, Haemophilus Influenza Type B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pentacel®</td>
<td>Sanofi Pasteur</td>
<td>1 SDV 5-pk</td>
<td>49281-0510-05</td>
<td>90698</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Haemophilus Influenza Type B (Hib)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ActHIB®</td>
<td>Sanofi Pasteur</td>
<td>10 mcg w/diluent</td>
<td>49281-0545-05</td>
<td>90648</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>HIBERIX®</td>
<td>GSK</td>
<td>0.5 mL SDV 10-pk</td>
<td>58160-0818-11</td>
<td>90648</td>
<td>TBD</td>
<td>Yes</td>
</tr>
<tr>
<td>PedvaxHIB®</td>
<td>Merck‡</td>
<td>0.5 mL SDV 10-pk</td>
<td>00006-4897-00</td>
<td>90647</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Hepatitis A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HAVRIX®</td>
<td>GSK</td>
<td>720 EL.U./0.5 mL SDV 10-pk</td>
<td>58160-0825-11</td>
<td>90633</td>
<td>TBD</td>
<td>Yes</td>
</tr>
<tr>
<td>HAVRIX®</td>
<td>GSK</td>
<td>720 EL.U./0.5 mL PFS 10-pk</td>
<td>58160-0825-52</td>
<td>90633</td>
<td>TBD</td>
<td>Yes</td>
</tr>
<tr>
<td>VAQTA®</td>
<td>Merck‡</td>
<td>25 U/0.5 mL SDV 10-pk</td>
<td>00006-4831-41</td>
<td>90633</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Hepatitis B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENGERIX-B®</td>
<td>GSK</td>
<td>10 mcg/0.5 mL SDV 10-pk</td>
<td>58160-0820-11</td>
<td>90744</td>
<td>TBD</td>
<td>Yes</td>
</tr>
<tr>
<td>ENGERIX-B®</td>
<td>GSK</td>
<td>10 mcg/0.5 mL PFS 10-pk</td>
<td>58160-0820-52</td>
<td>90744</td>
<td>TBD</td>
<td>Yes</td>
</tr>
<tr>
<td>RECOMBIVAX HB®</td>
<td>Merck‡</td>
<td>5 mcg/0.5 mL 10-pk</td>
<td>00006-4981-00</td>
<td>90744</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Human Papillomavirus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GARDASIL® 9</td>
<td>Merck‡</td>
<td>0.5 mL PFS 10-pk</td>
<td>00006-4119-03</td>
<td>90651</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Japanese Encephalitis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IXIARO®</td>
<td>Valneva</td>
<td>0.5 mL PFS</td>
<td>42515-0002-01</td>
<td>90738</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Measles, Mumps, Rubella</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M-M-R® II</td>
<td>Merck‡</td>
<td>0.5 mL SDV 10-pk</td>
<td>00006-4681-00</td>
<td>90707</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Measles, Mumps, Rubella, Varicella</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ProQuad®</td>
<td>Merck‡</td>
<td>0.5 mL SDV 10-pk</td>
<td>00006-4171-00</td>
<td>90710</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Meningococcal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BEXSERO®</td>
<td>GSK</td>
<td>0.5 mL PFS</td>
<td>58160-0976-06</td>
<td>90620</td>
<td>TBD</td>
<td>Yes</td>
</tr>
<tr>
<td>BEXSERO®</td>
<td>GSK</td>
<td>0.5 mL PFS 10-pk</td>
<td>58160-0976-20</td>
<td>90620</td>
<td>TBD</td>
<td>Yes</td>
</tr>
<tr>
<td>Menactra®</td>
<td>Sanofi Pasteur</td>
<td>1 SDV 5-pk</td>
<td>49281-0589-05</td>
<td>90734</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>MENVEO® Lyophilized</td>
<td>GSK</td>
<td>0.5 mL SDV 10-pk</td>
<td>58160-0958-01</td>
<td>90734</td>
<td>TBD</td>
<td>Yes</td>
</tr>
<tr>
<td>TRUMENBA®</td>
<td>Pfizer</td>
<td>0.5 mL PFS 5-pk</td>
<td>00005-0100-05</td>
<td>90621</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>TRUMENBA®</td>
<td>Pfizer</td>
<td>0.5 mL PFS 10-pk</td>
<td>00005-0100-10</td>
<td>90621</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

†Have questions about Merck vaccines, including reimbursement support? Call the Merck Vaccine Customer Center at (866) 675-8899 M-F.

*All codes should be verified between the provider and the payer. | VIPc - Verified Inventory Program-Consignment (VIPc™) | 340B - Public Health Services 340B Pricing Available.
# Pediatric Vaccine Products

<table>
<thead>
<tr>
<th>Product</th>
<th>Manufacturer</th>
<th>Size</th>
<th>NDC ‡</th>
<th>Code*</th>
<th>VIPc 340B</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pneumococcal</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PREVNAR 13*</td>
<td>Pfizer</td>
<td>0.5 mL PFS 10-pk</td>
<td>00005-1971-02</td>
<td>90670</td>
<td>Yes No</td>
</tr>
<tr>
<td><strong>Polio</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IPOL*</td>
<td>Sanofi Pasteur</td>
<td>5 mL MDV</td>
<td>49281-0860-10</td>
<td>90713</td>
<td>No No</td>
</tr>
<tr>
<td><strong>Rabies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imovax® Rabies</td>
<td>Sanofi Pasteur</td>
<td>1 SDV w/diluent</td>
<td>49281-0250-51</td>
<td>90675</td>
<td>Yes No</td>
</tr>
<tr>
<td>RabAvert®</td>
<td>GSK</td>
<td>1.0 mL single dose kit</td>
<td>58160-0964-12</td>
<td>90675</td>
<td>TBD Yes</td>
</tr>
<tr>
<td><strong>Rotavirus</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ROTARIX®</td>
<td>GSK</td>
<td>1 mL SDV 10-pk</td>
<td>58160-854-52</td>
<td>90681</td>
<td>TBD Yes</td>
</tr>
<tr>
<td>RotaTeq®</td>
<td>Merck‡</td>
<td>2 mL 10-pk</td>
<td>00006-4047-41</td>
<td>90680</td>
<td>Yes No</td>
</tr>
<tr>
<td>RotaTeq®</td>
<td>Merck‡</td>
<td>2 mL 25-pk</td>
<td>00006-4047-20</td>
<td>90680</td>
<td>Yes No</td>
</tr>
<tr>
<td><strong>Tetanus, Diphtheria, Pertussis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adacel® (Tdap)</td>
<td>Sanofi Pasteur</td>
<td>5 PFS/bx</td>
<td>49281-0400-15</td>
<td>90715</td>
<td>Yes No</td>
</tr>
<tr>
<td>Adacel® (Tdap)</td>
<td>Sanofi Pasteur</td>
<td>10 SDV/bx</td>
<td>49281-0400-10</td>
<td>90715</td>
<td>Yes No</td>
</tr>
<tr>
<td>BOOSTRIX®</td>
<td>GSK</td>
<td>0.5 mL SDV 10-pk</td>
<td>58160-0842-11</td>
<td>90715</td>
<td>TBD Yes</td>
</tr>
<tr>
<td>BOOSTRIX®</td>
<td>GSK</td>
<td>0.5 mL PFS</td>
<td>58160-0842-34</td>
<td>90715</td>
<td>TBD Yes</td>
</tr>
<tr>
<td>BOOSTRIX®</td>
<td>GSK</td>
<td>0.5 mL PFS 10-pk</td>
<td>58160-0842-52</td>
<td>90715</td>
<td>TBD Yes</td>
</tr>
<tr>
<td><strong>Tetanus, Diphtheria</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diphtheria and Tetanus Toxoids Adsorbed</td>
<td>Sanofi Pasteur</td>
<td>10 SDV PF Peds</td>
<td>49281-0225-10</td>
<td>90714</td>
<td>Yes No</td>
</tr>
<tr>
<td>TENIVAC®</td>
<td>Sanofi Pasteur</td>
<td>10 PFS/bx</td>
<td>49281-0215-15</td>
<td>90714</td>
<td>Yes No</td>
</tr>
<tr>
<td>Tetanus and Diphtheria Toxoids Adsorbed</td>
<td>Grifols</td>
<td>0.5 mL vial 10-pk</td>
<td>13533-0131-01</td>
<td>90714</td>
<td>No No</td>
</tr>
<tr>
<td><strong>Tuberculosis Testing</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TUBERSOL®*</td>
<td>Sanofi Pasteur</td>
<td>1 mL vial 10 test</td>
<td>49281-0752-21</td>
<td>86580</td>
<td>Yes No</td>
</tr>
<tr>
<td>TUBERSOL®*</td>
<td>Sanofi Pasteur</td>
<td>5 mL vial 50 test</td>
<td>49281-0752-22</td>
<td>86580</td>
<td>Yes No</td>
</tr>
<tr>
<td><strong>Typhoid</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Typhim Vi®</td>
<td>Sanofi Pasteur</td>
<td>0.5 mL MDV</td>
<td>49281-0790-20</td>
<td>90691</td>
<td>Yes No</td>
</tr>
<tr>
<td>Typhim Vi®</td>
<td>Sanofi Pasteur</td>
<td>0.5 mL PFS</td>
<td>49281-0790-51</td>
<td>90691</td>
<td>Yes No</td>
</tr>
<tr>
<td>Vivotif®</td>
<td>PaxVax</td>
<td>4 capsule blister pack</td>
<td>69401-0000-01</td>
<td>90690</td>
<td>Yes No</td>
</tr>
<tr>
<td><strong>Varicella</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VARIVAX®</td>
<td>Merck‡</td>
<td>0.5 mL SDV 10-pk</td>
<td>00006-4827-00</td>
<td>90716</td>
<td>No No</td>
</tr>
</tbody>
</table>

‡TUBERSOL® is used for intradermal tuberculin testing in humans. It is not a vaccine.

*Have questions about Merck vaccines, including reimbursement support? Call the Merck Vaccine Customer Center at (866) 675-8899 M-F.

*All codes should be verified between the provider and the payer.  | VIPc - Verified Inventory Program-Consignment (VIPc™)  | 340B - Public Health Services 340B Pricing Available.

Emergency Ordering 24/7  | (800) 843-7477  | FFFenterprises.com  | FAX (800) 418-4333  | biosupply.fffenterprises.com
### Pediatric Vaccine Products

<table>
<thead>
<tr>
<th>Product</th>
<th>Manufacturer</th>
<th>Size</th>
<th>NDC‡</th>
<th>Code*</th>
<th>VIPc</th>
<th>340B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flucelvax®</td>
<td>Seqirus</td>
<td>0.5 mL PFS 10-bx</td>
<td>70461-0318-03</td>
<td>90674</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Flucelvax®</td>
<td>Seqirus</td>
<td>5 mL MDV</td>
<td>70461-0418-10</td>
<td>90756</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Afluria®</td>
<td>Seqirus</td>
<td>0.5 mL PFS 10-bx</td>
<td>33332-0318-01</td>
<td>90686</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Afluria®</td>
<td>Seqirus</td>
<td>5 mL MDV</td>
<td>33332-0418-10</td>
<td>90688</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Fluzone® Pediatric</td>
<td>Sanofi Pasteur</td>
<td>0.25 mL PFS 10-bx</td>
<td>49281-0518-25</td>
<td>90685/90687</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Fluzone®</td>
<td>Sanofi Pasteur</td>
<td>0.5 mL PFS 10-bx</td>
<td>49281-0418-50</td>
<td>90686</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Fluzone®</td>
<td>Sanofi Pasteur</td>
<td>0.5 mL SDV 10-bx</td>
<td>49281-0418-10</td>
<td>90686</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Fluzone®</td>
<td>Sanofi Pasteur</td>
<td>5 mL MDV</td>
<td>49281-0629-15</td>
<td>90688</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>FLULAVAL®</td>
<td>GSK</td>
<td>0.5 mL PFS 10-bx</td>
<td>19515-0909-52</td>
<td>90686</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>FLULAVAL®</td>
<td>GSK</td>
<td>5 mL MDV</td>
<td>19515-0900-11</td>
<td>90688</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>FLUARIX®</td>
<td>GSK</td>
<td>0.5 mL PFS 10-bx</td>
<td>58160-0898-52</td>
<td>90686</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>FluMist®</td>
<td>MedImmune</td>
<td>0.2 mL spray 10-bx</td>
<td>66019-0305-10</td>
<td>90672</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

**Want priority access on FLU VACCINES for the 2019-2020 season?**


- Priority access on advance released flu vaccines
- No minimum purchase
- Hassle-free
- Guaranteed booking for the products you need

---

\*Have questions about Merck vaccines, including reimbursement support? Call the Merck Vaccine Customer Center at (866) 675-8899 M-F.

\*All codes should be verified between the provider and the payer. | VIPc - Verified Inventory Program-Consignment (VIPc™) | 340B - Public Health Services 340B Pricing Available.

Emergency Ordering 24/7 | (800) 843-7477 | FFFenterprises.com | FAX (800) 418-4333 | biosupply.ffenterprises.com
### Pediatric Immunization Schedule

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Birth</th>
<th>1 mo</th>
<th>2 mos</th>
<th>4 mos</th>
<th>6 mos</th>
<th>9 mos</th>
<th>12 mos</th>
<th>15 mos</th>
<th>18 mos</th>
<th>19-23 mos</th>
<th>2-3 yrs</th>
<th>4-6 yrs</th>
<th>7-10 yrs</th>
<th>11-12 yrs</th>
<th>13-15 yrs</th>
<th>16 yrs</th>
<th>17-18 yrs</th>
</tr>
</thead>
<tbody>
<tr>
<td>HepB (Hepatitis B)</td>
<td>1st</td>
<td>2nd</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(RV) RV1: 2-dose series</td>
<td>1st</td>
<td>2nd</td>
<td>3rd</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(RV) RV5: 3-dose series</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DTaP: &lt;7 yrs</td>
<td>1st</td>
<td>2nd</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3rd</td>
<td>4th</td>
<td>5th</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Diphtheria, Tetanus, &amp; Acellular Pertussis)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hib (Haemophilus Influenzae Type B)</td>
<td>1st</td>
<td>2nd</td>
<td>3rd</td>
<td>3rd or 4th</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCV13 (Pneumococcal Conjugate)</td>
<td>1st</td>
<td>2nd</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3rd</td>
<td>4th</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IPV: &lt;18 yrs (Inactivated poliovirus)</td>
<td>1st</td>
<td>2nd</td>
<td></td>
<td>3rd</td>
<td></td>
<td></td>
<td>4th</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza (IV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Annual vaccination (IIV) 1 or 2 doses</td>
<td>Annual vaccination (IIV) 1 dose only</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MMR (Measles, Mumps, Rubella)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>See footnote 8</td>
<td>1st dose</td>
<td>2nd dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VAR (Varicella)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>See footnote 4</td>
<td>1st dose</td>
<td>2nd dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HepA (Hepatitis A)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>See footnote 4</td>
<td>1st dose</td>
<td>2nd dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MenACWY-D≥9 mos; MenACWY-CRM ≥2 mos (Meningococcal)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>See footnote 4</td>
<td>1st dose</td>
<td>2nd dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tdap: &gt;7 yrs (Tetanus, Diphtheria, &amp; Acellular Pertussis)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>See footnote 14</td>
<td></td>
<td>Tdap</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV (Human papillomavirus)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>See footnote 14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>See footnote 14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PPSV23 (Pneumococcal polysaccharide)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>See footnote 14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Per the Centers for Disease Control and Prevention, the above recommendations must be read along with the footnotes of this schedule.

*Footnotes:*
- 1: $HepB$ (Hepatitis B) 1st dose
- 2: See footnote 2
- 3: See footnote 3
- 4: See footnote 4
- 5: See footnote 5
- 6: See footnote 6
- 7: See footnote 7
- 8: See footnote 8
- 9: See footnote 9
- 10: See footnote 10
- 11: See footnote 11
- 12: See footnote 12
- 13: See footnote 13
- 14: See footnote 14
- CV: Combined vaccine

Content Source: Centers for Disease Control and Prevention - Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger, United States, 2018 - www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf
Footnotes — Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger, UNITED STATES, 2018

For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html. For vaccine recommendations for persons 19 years of age and older, see the Adult Immunization Schedule.

Additional information
- For information on contraindications and precautions for the use of a vaccine, consult the General Best Practice Guidelines for Immunization and relevant ACIP statements, at www.cdc.gov/vaccines/hcp/acip-recs/index.html.
- For calculating intervals between doses, 4 weeks = 28 days. Intervals of ≥4 months are determined by calendar months.
- Within a number range (e.g., 12–18), a dash (–) should be read as “through.”
- Vaccine doses administered ≤4 days before the minimum age or interval are considered valid. Doses of any vaccine administered ≥5 days earlier than the minimum interval or minimum age should not be counted as valid and should be repeated as age-appropriate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. For further details, see Table 3-1, Recommended and minimum ages and intervals between vaccine doses, in General Best Practice Guidelines for Immunization at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html.
- Information on travel vaccine requirements and recommendations is available at wwwnc.cdc.gov/travel/.
- The National Vaccine Injury Compensation Program (VICP) is a no-fault alternative to the traditional legal system for resolving vaccine injury claims. All routine child and adolescent vaccines are covered by VICP except for pneumococcal polysaccharide vaccine (PPSV23). For more information; see www.hrsa.gov/vaccinecompensation/index.html.

1. Hepatitis B (HepB) vaccine. (minimum age: birth)  
   Birth Dose (Monovalent HepB vaccine only):
   - **Mother is HBsAg-Negative:** 1 dose within 24 hours of birth for medically stable infants ≥2,000 grams. Infants <2,000 grams administer 1 dose at chronological age 1 month or hospital discharge.
   - **Mother is HBsAg-Positive:**
     - Give HepB vaccine and 0.5 mL of HBIG (at separate anatomic sites) within 12 hours of birth, regardless of birth weight.
     - Test for HBsAg and anti-HBs at age 9–12 months. If HepB series is delayed, test 1–2 months after final dose.
   - **Mother’s HBsAg status is unknown:**
     - Give HepB vaccine within 12 hours of birth, regardless of birth weight.
     - For infants <2,000 grams, give 0.5 mL of HBIG in addition to HepB vaccine within 12 hours of birth.
     - Determine mother’s HBsAg status as soon as possible. If mother is HBsAg-positive, give 0.5 mL of HBIG to infants ≥2,000 grams as soon as possible, but no later than 7 days of age.

   **Routine Series:**
   - A complete series is 3 doses at 0, 1–2, and 6–18 months. (Monovalent HepB vaccine should be used for doses given before age 6 weeks.)
   - Infants who did not receive a birth dose should begin the series as soon as feasible (see Figure 2).
   - Administration of 4 doses is permitted when a combination vaccine containing HepB is used after the birth dose.
   - **Minimum age** for the final (3rd or 4th) dose: 24 weeks.
   - **Minimum Intervals:** Dose 1 to Dose 2: 4 weeks / Dose 2 to Dose 3: 8 weeks / Dose 1 to Dose 3: 16 weeks. (When 4 doses are given, substitute “Dose 4” for “Dose 3” in these calculations.)

   **Catch-up vaccination:**
   - Unvaccinated persons should complete a 3-dose series at 0, 1–2, and 6 months.
   - Adolescents 11–15 years of age may use an alternative 2-dose schedule, with at least 4 months between doses (adult formulation Recombivax HB only).
   - For other catch-up guidance, see Figure 2.

2. Rotavirus vaccines. (minimum age: 6 weeks)
   **Routine vaccination:**
   - 3-dose series at 2, 4, and 6 months.
     - **Rotarix:** 2-dose series at 2 and 4 months.
     - **RotaTeq:** 3-dose series at 2, 4, and 6 months.
   - If any dose in the series is either RotaTeq or unknown, default to 3-dose series.

   **Catch-up vaccination:**
   - Do not start the series on or after age 15 weeks, 0 days.
   - The maximum age for the final dose is 8 months, 0 days.
   - For other catch-up guidance, see Figure 2.

3. Diphtheria, tetanus, and acellular pertussis (DTaP) vaccine. (minimum age: 6 weeks [4 years for Kinrix or Quadracel])
   **Routine vaccination:**
   - 5-dose series at 2, 4, 6, and 15–18 months, and 4–6 years.
     - **Prospectively:** A 4th dose may be given as early as age 12 months if at least 6 months have elapsed since the 3rd dose.
     - **Retrospectively:** A 4th dose that was inadvertently given as early as 12 months may be counted if at least 4 months have elapsed since the 3rd dose.
   **Catch-up vaccination:**
   - The 5th dose is not necessary if the 4th dose was administered at 4 years or older.
   - For other catch-up guidance, see Figure 2.
4. **Haemophilus influenzae** type b (Hib) vaccine.
   *(minimum age: 6 weeks)*
   **Routine vaccination:**
   - ActHIB, Hibrix, or Pentacel: 4-dose series at 2, 4, 6, and 12–15 months.
   - PedvaxHIB: 3-dose series at 2, 4, and 12–15 months.
   **Catch-up vaccination:**
   - 1st dose at 7–11 months: Give 2nd dose at least 4 weeks later and 3rd (final) dose at 12–15 months or 8 weeks after 2nd dose (whichever is later).
   - 1st dose at 12–14 months: Give 2nd (final) dose at least 8 weeks after 1st dose.
   - 1st dose before 12 months and 2nd dose before 15 months: Give 3rd (final) dose 8 weeks after 2nd dose.
   - 2 doses of PedvaxHIB before 12 months: Give 3rd (final) dose at 12–59 months and at least 8 weeks after 2nd dose.
   - Unvaccinated at 15–59 months: 1 dose.
   - For other catch-up guidance, see Figure 2.

**Special Situations:**
- **Chemotherapy or radiation treatment** 12–59 months
  - Unvaccinated or only 1 dose before 12 months: Give 2 doses, 8 weeks apart
  - 2 or more doses before 12 months: Give 1 dose, at least 8 weeks after previous dose.
- **Hematopoietic stem cell transplant (HSCT)**
  - 3-dose series with doses 4 weeks apart starting 6 to 12 months after successful transplant (regardless of Hib vaccination history).
- **Anatomic or functional asplenia (including sickle cell disease)** 12–59 months
  - Unvaccinated or only 1 dose before 12 months: Give 2 doses, 8 weeks apart
  - 2 or more doses before 12 months: Give 1 dose, at least 8 weeks after previous dose.
  - *Unimmunized persons 5–18 years* 1 dose
- **Elective splenectomy**
  - Unimmunized persons 15 months or older 1 dose (preferably at least 14 days before procedure).

- **HIV infection** 12–59 months
  - Unvaccinated or only 1 dose before 12 months: Give 2 doses 8 weeks apart.
  - 2 or more doses before 12 months: Give 1 dose, at least 8 weeks after previous dose.
  - *Unimmunized persons 5–18 years* 1 dose
- **Immune deficiency, early component complement deficiency** 12–59 months
  - Unvaccinated or only 1 dose before 12 months: Give 2 doses, 8 weeks apart.
  - 2 or more doses before 12 months: Give 1 dose, at least 8 weeks after previous dose.

5. **Pneumococcal vaccines.** *(minimum age: 6 weeks [PCV13], 2 years [PPSV23])*
   **Routine vaccination with PCV13:**
   - 4-dose series at 2, 4, 6, and 12–15 months.
   **Catch-up vaccination with PCV13:**
   - 1 dose for healthy children aged 24–59 months with any incomplete* PCV13 schedule
   - For other catch-up guidance, see Figure 2.
   **Special situations: High-risk conditions:**
   - Administer PCV13 doses before PPSV23 if possible.
   - Chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure); chronic lung disease (including asthma treated with high-dose, oral, corticosteroids); diabetes mellitus;
   - Age 2–5 years:
     - Any incomplete* schedules with:
       - 3 PCV13 doses: 1 dose of PCV13 (at least 8 weeks after any prior PCV13 dose).
       - <3 PCV13 doses: 2 doses of PCV13, 8 weeks after the most recent dose and given 8 weeks apart.
     - No history of PPSV23: 1 dose of PPSV23 (at least 8 weeks after any prior PCV13 dose).
   - Age 6–18 years:
     - No history of either PCV13 or PPSV23: 1 dose of PCV13, 1 dose of PPSV23 at least 8 weeks later.
     - Any PCV13 but no PPSV23: 1 dose of PPSV23 at least 8 weeks after the most recent dose of PCV13
     - PPSV23 but no PCV13: 1 dose of PCV13 at least 8 weeks after the most recent dose of PPSV23.

**Sickle cell disease and other hemoglobinopathies; anatomic or functional asplenia; congenital or acquired immunodeficiency; HIV infection; chronic renal failure; nephrotic syndrome; malignant neoplasms, leukemias, lymphomas, Hodgkin disease, and other diseases associated with treatment with immunosuppressive drugs or radiation therapy; solid organ transplantation; multiple myeloma:**
   - **Age 2–5 years:**
     - Any incomplete* schedules with:
       - 3 PCV13 doses: 1 dose of PCV13 (at least 8 weeks after any prior PCV13 dose).
       - <3 PCV13 doses: 2 doses of PCV13, 8 weeks after the most recent dose and given 8 weeks apart.
     - No history of PPSV23: 1 dose of PPSV23 at least 8 weeks after any prior PCV13 dose.
   - **Age 6–18 years:**
     - No history of either PCV13 or PPSV23: 1 dose of PCV13, 1 dose of PPSV23 at least 8 weeks later.
     - Any PCV13 but no PPSV23: 1 dose of PPSV23 at least 8 weeks after the most recent dose of PCV13
     - PPSV23 but no PCV13: 1 dose of PCV13 at least 8 weeks after the most recent dose of PPSV23.
For further guidance on the use of the vaccines mentioned below, see: www.cdc.gov/vaccines/hcp/acip-recs/index.html.

7. Influenza vaccines. (minimum age: 6 months)
   **Routine vaccination:**
   - Administer an age-appropriate formulation and dose of influenza vaccine annually.
     - **Children 6 months–8 years** who did not receive at least 2 doses of influenza vaccine before July 1, 2017 should receive 2 doses separated by at least 4 weeks.
     - **Persons 9 years and older**
       - Live attenuated influenza vaccine (LAIV) not recommended for the 2017–18 season.
     
   **Catch-up vaccination:**
   - In the first 6 months of life, use minimum ages and intervals only for travel to a polio-endemic region or during an outbreak.
   - If 4 or more doses were given before the 4th birthday, give 1 more dose at age 4–6 years and at least 6 months after the previous dose.
   
   **Special populations:**
   - Persons who work with hepatitis A virus in a research laboratory or with non-human primates
   
8. Measles, mumps, and rubella (MMR) vaccine. (minimum age: 12 months for routine vaccination)
   **Routine vaccination:**
   - 2-dose series: 12–15 months and 4–6 years.
   - The 2nd dose may be given as early as 4 weeks after the 1st dose.
   
   **Catch-up vaccination:**
   - Unvaccinated children and adolescents: 2 doses at least 4 weeks apart.
   
   **International travel:**
   - Infants 6–11 months: 1 dose before departure.
   - Revaccinate with 2 doses at 12–15 months (12 months for children in high-risk areas) and 2nd dose as early as 4 weeks later.
   - Unvaccinated children 12 months and older: 2 doses at least 4 weeks apart before departure.
   
   **Mumps outbreak:**
   - Persons ≥12 months who previously received ≤2 doses of mumps-containing vaccine and are identified by public health authorities to be at increased risk during a mumps outbreak should receive a dose of mumps-virus containing vaccine.

9. Varicella (VAR) vaccine. (minimum age: 12 months)
   **Routine vaccination:**
   - 2-dose series: 12–15 months and 4–6 years.
   - The 2nd dose may be given as early as 3 months after the 1st dose (a dose given after a 4-week interval may be counted).

   **Catch-up vaccination:**
   - Ensure persons 7–18 years without evidence of immunity (see MMWR 2007;56[No. RR-4], at www.cdc.gov/mmwr/pdf/rr/rr5604.pdf) have 2 doses of varicella vaccine:
     - **Ages 7–12:** routine interval 3 months (minimum interval: 4 weeks).
     - **Ages 13 and older:** minimum interval 4 weeks.

10. Hepatitis A (HepA) vaccine. (minimum age: 12 months)
   **Routine vaccination:**
   - 2 doses, separated by 6-18 months, between the 1st and 2nd birthdays. (A series begun before the 2nd birthday should be completed even if the child turns 2 before the second dose is given.)
   
   **Catch-up vaccination:**
   - Anyone 2 years of age or older may receive HepA vaccine if desired. Minimum interval between doses is 6 months.

   **Special populations:**
   - Previously unvaccinated persons who should be vaccinated:
     - Persons traveling to or working in countries with high or intermediate endemicity
     - Men who have sex with men
     - Users of injection and non-injection drugs
     - Persons who work with hepatitis A virus in a research laboratory or with non-human primates
     - Persons with clotting-factor disorders
     - Persons with chronic liver disease
     - Persons who anticipate close, personal contact (e.g., household or regular babysitting) with an international adoptee during the first 60 days after arrival in the United States from a country with high or intermediate endemicity (administer the 1st dose as soon as the adoption is planned—ideally at least 2 weeks before the adoptee’s arrival).

11. Serogroup A, C, W, Y meningococcal vaccines. (Minimum age: 2 months [Menveo], 9 months [Menactra])
   **Routine:**
   - 2-dose series: 11–12 years and 16 years.
   
   **Catch-Up:**
   - Age 13-15 years: 1 dose now and booster at age 16-18 years. Minimum interval 8 weeks.
   - Age 16-18 years: 1 dose.
Children 7–10 years who receive Tdap inadvertently or as part of the catch-up series may receive the routine Tdap dose at 11–12 years.

**DTaP inadvertently given after the 7th birthday:**
- Child 7–10: DTaP may count as part of catch-up series. Routine Tdap dose at 11-12 may be given.
- Adolescent 11–18: Count dose of DTaP as the adolescent Tdap booster.
- For other catch-up guidance, see Figure 2.

For further guidance on the use of the vaccines mentioned below, see: [www.cdc.gov/vaccines/hcp/acip-recs/index.html](http://www.cdc.gov/vaccines/hcp/acip-recs/index.html).

**12. Serogroup B meningococcal vaccines (minimum age: 10 years [Bexsero, Trumenba].)**
- **Clinical discretion:** Adolescents not at increased risk for meningococcal B infection who want MenB vaccine.
  - Bexsero: 2 doses at least 1 month apart.
  - Trumenba: 2 doses at least 6 months apart. If the 2nd dose is given earlier than 6 months, give a 3rd dose at least 4 months after the 2nd.

**Special populations and situations:** Anatomic or functional asplenia, sickle cell disease, persistent complement component deficiency (including eculizumab use):
- Bexsero: 2-dose series at least 1 month apart.
- Trumenba: 3-dose series at 0, 1–2, and 6 months.

**Note:** Bexsero and Trumenba are not interchangeable.

**13. Tetanus, diphtheria, and a cellular pertussis (Tdap) vaccine. (minimum age: 11 years for routine vaccinations, 7 years for catch-up vaccination)**

**Routine vaccination:**
- Adolescents 11–12 years of age: 1 dose.
- Pregnant adolescents: 1 dose during each pregnancy (preferably during the early part of gestational weeks 27–36).
- Tdap may be administered regardless of the interval since the last tetanus- and diphtheria-toxoid-containing vaccine.
- Persons aged 7–18 years not fully immunized with DTaP: 1 dose of Tdap as part of the catch-up series (preferably the first dose). If additional doses are needed, use Td.

**Catch-up vaccination:**
- Adolescents 13–18 who have not received Tdap: 1 dose, followed by a Td booster every 10 years.
- Persons aged 7–18 years not fully immunized with DTaP: 1 dose of Tdap as part of the catch-up series (preferably the first dose). If additional doses are needed, use Td.

**Children 7–10 years** who receive Tdap inadvertently or as part of the catch-up series may receive the routine Tdap dose at 11–12 years.

**14. Human papillomavirus (HPV) vaccine (minimum age: 9 years)**

**Routine and catch-up vaccination:**
- Routine vaccination for all adolescents at 11–12 years (can start at age 9) and through age 18 if not previously adequately vaccinated. Number of doses dependent on age at initial vaccination:
  - Age 9–14 years at initiation: 2-dose series at 0 and 1–6 months. Minimum interval: 5 months (repeat a dose given too soon at least 12 weeks after the invalid dose and at least 5 months after the 1st dose).
  - Age 15 years or older at initiation: 3-dose series at 0, 1–2 months, and 6 months. Minimum intervals: 4 weeks between 1st and 2nd dose; 12 weeks between 2nd and 3rd dose; 5 months between 1st and 3rd dose (repeat dose(s) given too soon at or after the minimum interval since the most recent dose).
- Persons who have completed a valid series with any HPV vaccine do not need any additional doses.

**Special situations:**
- History of sexual abuse or assault: Begin series at age 9 years.
- Immunocompromised* (including HIV) aged 9–26 years: 3-dose series at 0, 1–2 months, and 6 months.
- Pregnancy: Vaccination not recommended, but there is no evidence the vaccine is harmful. No intervention is needed for women who inadvertently received a dose of HPV vaccine while pregnant. Delay remaining doses until after pregnancy. Pregnancy testing not needed before vaccination.

*See MMWR, December 16, 2016;65(49):1405–1408, at [www.cdc.gov/mmwr/volumes/65/wr/pdfs/mm6549a5.pdf](http://www.cdc.gov/mmwr/volumes/65/wr/pdfs/mm6549a5.pdf).
Our BioSupply® online ordering system makes ordering your critical-care pharmaceuticals easy, fast and convenient. The online portal empowers you to order what you want, when you want it with just one click so you can better manage your inventory.

- Easily manage and place orders for multiple accounts
- Ability to view and download contracted price lists
- Schedule BioVision reports to receive them daily, weekly, monthly or quarterly
- Effortlessly locate specific products on the updated Product Catalog page
- Access drop-ship products directly from the manufacturer

Our MyFluVaccine™ (MFV) ordering portal makes it easy to purchase multiple flu vaccine product presentations from the top manufacturers and select preferred delivery dates. MFV offers Choice, Convenience and Safety through our Guaranteed Channel Integrity™.

- Single source for all flu vaccines offered for the 2018-19 season
- 30% returnability per presentation
- Split shipments between multiple delivery dates
- Price guarantee—FFF will never raise prices in times of shortage
- 60 day payment terms
- Free overnight shipping
- Free promotional materials, including flu posters, brochures and wall charts
Our Verified Inventory Program-Consignment (VIPc™) is a product consignment program that offers real-time inventory management to continuously monitors critical-care products, freeing you to focus on patient care.

- Eliminate carrying costs
- Real-time 24/7 monitoring
- Customized inventory levels
- Increased visibility of consignment inventory
- Accurate reporting for loading and dispensing activities
- Temperature alerts when specs are out of range
- High touch service from our field Sales representatives

BuyByeRx™ is an online pharmaceuticals marketplace that allows licensed healthcare providers to buy and sell excess and short-dated on-demand, critical-care and OTC drugs at significant savings.

- Save big on brand name and generic pharmaceuticals and OTC drugs
- Personal Buying Assistant notifies you when products become available
- Overcome product inventory challenges such as:
  - Stock rotation
  - Product demand
  - Generic product launches
  - National Drug Code changes
  - Current pharmacy practices for short-dated and excess products

FFFenterprises.com

BuyByeRx.com